FI950947A0 - Oraalisesti annettavat farmaseuttiset formulaatiot - Google Patents

Oraalisesti annettavat farmaseuttiset formulaatiot

Info

Publication number
FI950947A0
FI950947A0 FI950947A FI950947A FI950947A0 FI 950947 A0 FI950947 A0 FI 950947A0 FI 950947 A FI950947 A FI 950947A FI 950947 A FI950947 A FI 950947A FI 950947 A0 FI950947 A0 FI 950947A0
Authority
FI
Finland
Prior art keywords
pharmaceutical formulations
oral administration
raloxifene
ethers
pharmaceutically
Prior art date
Application number
FI950947A
Other languages
English (en)
Swedish (sv)
Other versions
FI950947A (fi
FI117042B (fi
Inventor
Lowell Lee Gibson
Kerry John Hartauer
Julian Larry Stowers
Stephanie Ann Sweetana
Arvind Lavji Thakkar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI950947A0 publication Critical patent/FI950947A0/fi
Publication of FI950947A publication Critical patent/FI950947A/fi
Application granted granted Critical
Publication of FI117042B publication Critical patent/FI117042B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
FI950947A 1994-03-02 1995-03-01 Oraalisesti annettavat farmaseuttiset formulaatiot FI117042B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20491594A 1994-03-02 1994-03-02
US20491594 1994-03-02
SG1997000220A SG65636A1 (en) 1994-03-02 1997-01-30 Orally administrable pharmaceutical formulations
SG9700220 1997-01-30

Publications (3)

Publication Number Publication Date
FI950947A0 true FI950947A0 (fi) 1995-03-01
FI950947A FI950947A (fi) 1995-09-03
FI117042B FI117042B (fi) 2006-05-31

Family

ID=26665140

Family Applications (1)

Application Number Title Priority Date Filing Date
FI950947A FI117042B (fi) 1994-03-02 1995-03-01 Oraalisesti annettavat farmaseuttiset formulaatiot

Country Status (22)

Country Link
EP (1) EP0670162B1 (fi)
JP (1) JP3574210B2 (fi)
CN (1) CN1098684C (fi)
AT (1) ATE211910T1 (fi)
AU (1) AU684882B2 (fi)
BR (1) BR9500758A (fi)
CA (1) CA2143263C (fi)
CZ (1) CZ286119B6 (fi)
DE (1) DE69524981T2 (fi)
DK (1) DK0670162T3 (fi)
ES (1) ES2166799T3 (fi)
FI (1) FI117042B (fi)
HU (1) HU225418B1 (fi)
IL (1) IL112746A (fi)
NO (1) NO314286B1 (fi)
NZ (1) NZ270588A (fi)
PL (1) PL178858B1 (fi)
PT (1) PT670162E (fi)
RU (1) RU2118540C1 (fi)
SG (1) SG65636A1 (fi)
SI (1) SI0670162T1 (fi)
ZA (1) ZA951497B (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
BR9708248A (pt) * 1996-03-26 1999-07-27 Lilly Co Eli Benzotiofenos formulações contendo os mesmos e metódos
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
RU2203060C2 (ru) 1996-10-30 2003-04-27 Эли Лилли Энд Компани Способ профилактики рака молочной железы
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
CA2394636A1 (en) * 1999-12-13 2001-06-14 Chugai Seiyaku Kabushiki Kaisha Compound having hydroxycarbonyl-halogenoalkyl side chains
JP4798924B2 (ja) * 1999-12-13 2011-10-19 中外製薬株式会社 ヒドロキシカルボニル−ハロゲノアルキル側鎖を有する化合物
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
PT1381384E (pt) * 2001-04-24 2011-09-01 Merck Patent Gmbh Terapia de combinação usando agentes anti-angiogénicos e tnfa
CA2499819A1 (en) 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
DK2054042T3 (da) 2006-06-30 2020-08-03 Iceutica Pty Ltd Fremgangsmåder til fremstilling af biologisk aktive forbindelser i nanopartikelform
WO2009049643A1 (en) * 2007-10-16 2009-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2242483B1 (en) * 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
ES2437916T3 (es) 2009-07-02 2014-01-15 Synthon B.V. Composición de raloxifeno
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
EP2925320B1 (en) * 2012-11-30 2021-02-17 Pharmathen S.A. Novel method for improving the bioavailability of low aqueous solubility drugs
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2018062964A1 (ko) * 2016-09-30 2018-04-05 한미약품 주식회사 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
RU2118540C1 (ru) 1998-09-10
CA2143263C (en) 2002-01-08
IL112746A0 (en) 1995-05-26
NO950799L (no) 1995-09-04
DE69524981D1 (de) 2002-02-21
AU1354895A (en) 1995-09-07
JPH07277973A (ja) 1995-10-24
NO314286B1 (no) 2003-03-03
FI950947A (fi) 1995-09-03
PL178858B1 (pl) 2000-06-30
DK0670162T3 (da) 2002-03-11
HUT72661A (en) 1996-05-28
EP0670162A1 (en) 1995-09-06
DE69524981T2 (de) 2002-08-29
CZ286119B6 (cs) 2000-01-12
CA2143263A1 (en) 1995-09-03
HU9500635D0 (en) 1995-04-28
CN1098684C (zh) 2003-01-15
AU684882B2 (en) 1998-01-08
PL307491A1 (en) 1995-09-04
EP0670162B1 (en) 2002-01-16
CZ49995A3 (en) 1995-10-18
IL112746A (en) 1999-12-31
BR9500758A (pt) 1995-10-24
CN1112420A (zh) 1995-11-29
ES2166799T3 (es) 2002-05-01
ZA951497B (en) 1996-08-23
JP3574210B2 (ja) 2004-10-06
FI117042B (fi) 2006-05-31
SI0670162T1 (en) 2002-06-30
SG65636A1 (en) 1999-06-22
HU225418B1 (en) 2006-11-28
NZ270588A (en) 1996-01-26
NO950799D0 (no) 1995-03-01
PT670162E (pt) 2002-06-28
ATE211910T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
FI950947A (fi) Oraalisesti annettavat farmaseuttiset formulaatiot
HRP20000494B1 (en) Pharmaceutically active morpholinol
ITBO910024A1 (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
ATE238036T1 (de) Autoklavierbare pharmazeutische zusammensetzungen mit komplexbildner
DZ1876A1 (fr) Médicaments pour administration orale.
IT8619675A0 (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale.
ITRM910696A0 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
AU6945491A (en) Pimobendan compositions
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
IT1231012B (it) Composizione farmaceutica per uso orale contenente nac.
MY101566A (en) Pharmaceutical compositions.
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
ITRM920535A0 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
IT1243358B (it) Composizioni farmaceutiche per la somministrazione orale di irudina
IT8621395A0 (it) Composizione farmaceutica orale a base di ubichinoni.
MY117590A (en) Orally administerable pharmaceutical formulations
IT8467927A1 (it) Preparati farmaceutici a base di dobutamina somministrabili por via orale.
FI903885A0 (fi) Ny oral farmaceutisk doseringsform som foerbaettrar biotillgaengligheten.
DE69208913T2 (de) 2-Oxindol-1-carboxamidderivat enthaltendes Arzneimittel zur rektalen Verabreichung
IT8819541A0 (it) Composizione farmaceutica per somministrazione nasale.
IE900393L (en) Pharmaceutical compositions for oral administration
ITPD920141A1 (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
ATA172297A (de) Pharmazeutische orale zusammensetzung enthaltend fk506

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117042

Country of ref document: FI

MM Patent lapsed